newsfilter
← Latest News
Business Wire·

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate JANX011